

EPL

Estimate change	<b></b>
TP change	T.
Rating change	$\longleftrightarrow$

Bloomberg	EPLL IN
Equity Shares (m)	319
M.Cap.(INRb)/(USDb)	79.6 / 0.9
52-Week Range (INR)	290 / 170
1, 6, 12 Rel. Per (%)	2/21/23
12M Avg Val (INR M)	392

### Financials & Valuations (INR b)

		- 1	
Y/E Mar	2025E	2026E	2027E
Sales	41.9	45.9	50.0
EBITDA	8.3	9.8	10.8
PAT	3.4	4.5	5.3
EBITDA (%)	19.7	21.3	21.6
EPS (INR)	10.6	14.1	16.6
EPS Gr. (%)	30.6	32.8	18.2
BV/Sh. (INR)	71.3	80.4	92.0
Ratios			
Net D/E	0.1	-0.0	-0.2
RoE (%)	15.5	18.6	19.3
RoCE (%)	14.8	16.6	18.0
Payout (%)	47.2	35.5	30.0
Valuations			
P/E (x)	23.5	17.7	15.0
EV/EBITDA (x)	10.0	8.1	6.9
Div Yield (%)	2.0	2.0	2.0
FCF Yield (%)	6.4	6.3	7.2

#### Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	51.5	51.5	51.5
DII	11.6	11.2	14.5
FII	14.9	13.4	9.9
Others	22.0	23.9	24.1

Note: FII includes depository receipts

#### **CMP: INR250** TP: INR300 (+20%) Buy

## **Europe and the Americas continue to drive operating performance Operating performance below estimate**

- EPL reported an EBITDA of INR2b (+10%YoY) in 3QFY25, below estimates due to lower-than-expected performance of AMESA (down ~9.5% YoY) and EAP (~down 2.9% YoY), primarily driven by the slowdown in the Indian market and currency depreciation in Egypt, respectively. The Americas and Europe grew by 30% YoY and 2.2x YoY, respectively
- Strong margins in Europe and the Americas are expected to sustain, supported by cost optimization, an improving sales mix, and a robust demand scenario in Brazil, which is leading the company to fast-track its capacity addition plans in the region.
- We broadly maintain our estimates for FY25/FY26/FY27 and value the stock at 18x FY27E EPS to arrive at our TP of INR300. Reiterate BUY.

#### Margin expansion across key markets drives profitability

- Revenue grew ~4% YoY to INR10.1b (Est. INR10.6b). Gross margin expanded 200bp YoY to 60.2%. EBITDA margin expanded 107bp YoY to 19.9% (est. 20.2%), led by improving margins in the Americas and Europe. EBITDA stood at INR2b (est. INR2.2b), up 10% YoY. Adj. PAT grew 9% YoY to INR935m (est.INR922m).
- Revenue from the Americas/Europe/AMESA grew 7%/9%/1% YoY to INR2.7b/INR2.2b/INR3.5b, while revenue from EAP declined by 1% YoY to INR2.5b. EBITDA margin expanded 340bp/930bp YoY for Americas/Europe to 19.6%/18.4%, whereas EBITDA margin contracted for AMESA/EAP by 210bp/50bp YoY to 17.7%/21.2%. EBITDA for Americas/ Europe grew 30%/2.2x YoY to INR532m/INR415m, while it declined for AMESA/EAP by 9.5%/2.9% YoY to INR627m/INR530m during the quarter.
- In 9MFY25, revenue/EBITDA/adj. PAT grew by 8%/16%/28% YoY to INR31b/INR6b/INR2.4b.

#### Highlights from the management commentary

- Guidance: EPL expects double-digit revenue growth, strong EBITDA margins, and steady tax rates (20-22%) while actively managing raw material costs, forex volatility, and geopolitical risks.
- Expansion: Thailand's new Beauty & Cosmetics facility will enhance localization, enable faster delivery, and tap into a 1.5b unit annual market, expanding EPL's reach in Indonesia, Vietnam, and Malaysia.
- **US tariffs:** US operations remain unaffected by potential tariffs, with domestic manufacturing and India-sourced laminates. EPL could gain market share if China faces trade restrictions.

MOTILAL OSWAL

### **Valuation and view**

■ EPL experienced strong growth in the Americas and Europe, driven by a favorable product mix, a trend we expect to sustain moving forward.

Additionally, the recovery in AMESA and EAP markets will be supported by a scale-up in exports from India and further expansion into this region driven by the new facility in Thailand, respectively.

We expect a CAGR of 9%/15%/27% in revenue/EBITDA/adjusted PAT over FY24-27. We value the stock at 18x FY27E EPS to arrive at our TP of INR300. Reiterate BUY.

Y/E March		FY	24			FY25				FY25E	FY25E	Var
•	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3Q	%
Gross Sales	9,102	10,016	9,751	10,292	10,074	10,862	10,143	10,817	39,161	41,896	10,663	-5
YoY Change (%)	9.4	5.6	3.2	6.2	10.7	8.4	4.0	5.1	6.0	7.0	0.0	
Total Expenditure	7,512	8,206	7,917	8,383	8,216	8,657	8,127	8,640	32,018	33,640	8,442	
EBITDA	1,590	1,810	1,834	1,909	1,858	2,205	2,016	2,177	7,143	8,256	2,220	-9
Margins (%)	17.5	18.1	18.8	18.5	18.4	20.3	19.9	20.1	18.2	19.7	20.8	
Depreciation	800	836	842	850	836	852	863	920	3,328	3,471	880	
Interest	235	306	294	321	290	291	274	270	1,156	1,125	285	
Other Income	100	96	237	161	65	140	127	130	594	462	167	
PBT before EO expense	655	764	935	899	797	1,202	1,006	1,117	3,253	4,122	1,222	
Extra-Ord expense	0	0	0	605	0	0	0	0	605	0	0	
PBT	655	764	935	294	797	1,202	1,006	1,117	2,648	4,122	1,222	
Tax	106	254	70	152	139	301	64	273	582	777	296	
Rate (%)	16.2	33.2	7.5	51.7	17.4	25.0	6.4	24.4	22.0	18.8	24.2	
Minority Interest & Profit/Loss of												
Asso. Cos.	-6	-5	-4	81	-16	-31	-7	86	66	32	-4	
Reported PAT	543	505	861	223	642	870	935	930	2,132	3,377	922	
Adj PAT	543	505	861	677	642	870	935	930	2,586	3,377	922	1
YoY Change (%)	57.4	9.3	37.1	-19.7	18.2	72.3	8.6	37.5	13.5	30.6	7.1	
Margins (%)	6.0	5.0	8.8	6.6	6.4	8.0	9.2	8.6	6.6	8.1	8.7	

Exhibit 1: Ke	y performance	indicators
---------------	---------------	------------


Y/E March	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25		
Segment Revenue Gr. (%)											
AMESA	9%	8%	5%	5%	-1%	5%	9%	4%	1%		
EAP	-8%	9%	11%	13%	12%	4%	14%	9%	-1%		
Americas	19%	17%	10%	13%	12%	16%	19%	9%	7%		
Europe	10%	20%	8%	6%	9%	2%	9%	21%	9%		
Segment EBITDA Margin (%)											
AMESA	21%	22%	22%	20%	21%	20%	19%	18%	18%		
EAP	22%	18%	23%	23%	22%	18%	22%	22%	21%		
Americas	12%	10%	10%	12%	16%	18%	16%	18%	20%		
Europe	6%	11%	11%	10%	9%	11%	14%	17%	18%		
Cost Break-up (%)											
RM Cost (% of sales)	45%	46%	42%	43%	42%	43%	40%	42%	40%		
Employee Cost (% of sales)	19%	18%	20%	19%	20%	19%	21%	19%	21%		
Other Cost (% of sales)	21%	20%	20%	20%	20%	20%	20%	19%	20%		
Gross Margins (%)	55%	54%	58%	57%	58%	57%	60%	58%	60%		
EBITDA Margins (%)	16%	16%	17%	18%	19%	19%	18%	20%	20%		
EBIT Margins (%)	8%	8%	9%	10%	10%	10%	10%	12%	11%		

# **Key exhibits**

**Exhibit 2: Consolidated revenue trend** 


Revenue (INRm) **—O**— Growth (%) 10.7 10.1 9.4 8.4 7.0 4.0 9,751 10,074 10,143 10,292 10,862 9,693 9,102 10,016 9,449 1QFY24 **2QFY25** 

**Exhibit 3: Consolidated EBITDA trend** 



Source: Company, MOFSL

**Exhibit 4: Consolidated adjusted PAT trend** 



Source: Company, MOFSL

Source: Company, MOFSL

**Exhibit 5: AMESA region** 

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Revenue (INR m)	3,521	3,379	3,358	3,791	3,500	3,536	3,677	3,931	3,535
Growth (%)	9	8	5	5	-1	5	9	4	1
EBITDA (INR m)	731	756	732	754	749	703	700	712	627
Margin (%)	21	22	21.8	19.9	21.4	19.9	19.0	18.1	17.7
Growth (%)		32	15	14	2	-7	-4	-6	-16
EBIT (INR m)	404	423	365	446	392	414	430	440	341
Margin (%)	11	13	11	12	11	12	12	11	10
Growth (%)	14	53	18	34	-3	-2	18	-1	-13

Source: Company, MOFSL

**Exhibit 6: EAP region** 

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Revenue (INR m)	2,263	2,141	2,149	2,454	2,524	2,229	2,448	2,667	2,500
Growth (%)	-8	9	11	13	12	4	14	9	-1
EBITDA (INR m)	490	386	489	564	546	410	536	580	530
Margin (%)	22	18	22.8	23.0	21.6	18.4	21.9	21.7	21.2
Growth (%)		33	31	13	11	6	10	3	-3
EBIT (INR m)	365	248	351	428	412	271	392	431	379
Margin (%)	16	12	16	17	16	12	16	16	15
Growth (%)	-13	55	42	14	13	9	12	1	-8

Source: Company, MOFSL

**Exhibit 7: The Americas region** 

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Revenue (INR m)	2,260	2,299	2,178	2,519	2,528	2,664	2,589	2,757	2,713
Growth (%)	19	17	10	13	12	16	19	9	7
EBITDA (INR m)	274	223	210	312	409	478	408	492	532
Margin (%)	12	10	9.6	12.4	16.2	17.9	15.8	17.8	19.6
Growth (%)		619	-13	17	49	114	94	58	30
EBIT (INR m)	109	59	24	91	175	240	169	260	292
Margin (%)	5	3	1	4	7	9	7	9	11
Growth (%)	106	-69	-77	-14	61	307	604	186	67

Source: Company, MOFSL

**Exhibit 8: Europe region** 

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Revenue (INR m)	1,911	2,502	2,125	2,163	2,076	2,563	2,316	2,617	2,257
Growth (%)	10	20	8	6	9	2	9	21	9
EBITDA (INR m)	109	285	239	213	191	283	314	446	415
Margin (%)	6	11	11.2	9.8	9.2	11.0	13.6	17.0	18.4
Growth (%)		13	38	2	75	-1	31	109	117
EBIT (INR m)	-36	134	79	46	23	99	135	258	232
Margin (%)	-2	5	4	2	1	4	6	10	10
Growth (%)	64	29	132	-34	NA	-26	71	461	909

Source: Company, MOFSL



# Highlights from the management commentary

#### **Guidance & outlook**

- Despite near-term macroeconomic volatility, EPL is confident of delivering double-digit revenue growth over the medium term.
- EBITDA margins remain strong, with further improvement expected as restructuring benefits take effect.
- Europe and the Americas continue to expand margins, driven by cost optimization and an improved sales mix.
- Exports from India and China will be scaled up significantly, supported by additional business development teams.
- Raw material cost fluctuations are being actively managed, with pricing adjustments and efficiency measures ensuring minimal impact on margins.
- The company is focused on achieving EcoVadis Platinum Certification, reinforcing its position as a leader in sustainable packaging solutions.
- EPL remains agile in managing geopolitical risks, particularly in the context of the US election cycle and potential tariff changes.
- Management expects the long-term tax rate to remain in the 20-22% range, influenced by jurisdictional tax changes.

#### **Operating performance**

- India's EBITDA margins contracted to 17% due to lower revenue growth, higher personnel costs from increased sales investments, and an unfavorable Q3 product mix. However, corrective measures aim to recover 150bp in the coming quarters.
- EPL has achieved 10 consecutive quarters of EBITDA margin expansion, highlighting consistent operational efficiency and cost control.
- Net debt-to-EBITDA improved to 0.76x, reflecting strong cash flow generation and a commitment to deleveraging.

■ The Non-oral Care revenue mix increased to 48.7%, demonstrating a successful shift toward higher-margin Beauty & Cosmetics products.

### **Expansion & new investments**

- EPL is setting up a Beauty & Cosmetics manufacturing facility in Thailand to enable faster delivery and better localization, targeting a 1.5b unit annual market and expanding into Indonesia, Vietnam, and Malaysia.
- Due to strong Beauty & Cosmetics demand, EPL is accelerating its Brazil expansion, focusing on premium tubes with higher ASPs and superior EBITDA margins to strengthen its position in high-margin categories.
- The company has enhanced its capabilities in China by expanding from laminated tubes to extruded tubes, increasing its addressable market.
- Aggressive export strategies are being implemented to mitigate domestic challenges in China and capture growth in ASEAN markets.
- Despite short-term headwinds, EPL sees China as a key long-term market and continues to invest in its growth.

### **Regional performance**

- Europe benefited from restructuring, improved cost efficiencies, and better customer penetration, while the Americas' growth was driven by strong Beauty & Cosmetics demand and increased adoption of NeoSeam tubes.
- India & AMESA revenue grew just 1%, impacted by a temporary demand slowdown in India and currency depreciation in Egypt, though India saw a 5% YoY volume growth.
- Beauty & Cosmetics demand in India remained sluggish, but management expects a rebound in the coming quarters due to an expanding customer pipeline and strategic sales efforts.
- China's revenue declined 1% YoY due to macroeconomic headwinds, though domestic demand remained stable. EPL is expanding extruded tube production to diversify revenue and capture high-end market share.
- Brazil continues to outperform, particularly in Beauty & Cosmetics, prompting the company to fast-track capacity expansion, with additional production expected to go live in 1QFY26.
- The scalable business model in Brazil gives EPL confidence in replicating its success in other geographies.

#### Forex & US tariffs

- Currency devaluation in Brazil and Egypt impacted 3Q financials, but management expects forex movements to balance out over time.
- Operating in over 10 different currencies provides EPL with a natural hedge against forex volatility.
- Management anticipates some reversal in forex losses in 4Q, as the Brazilian
   Real and Egyptian Pound have recently strengthened.
- EPL does not expect major impact from potential US tariffs as its US operations are self-sufficient, with all tubes manufactured domestically and laminates now sourced from India instead of China.
- If tariffs are imposed on China, EPL could benefit by capturing additional market share from US buyers seeking alternative suppliers.

#### **Others**

- EPL's lower 3QFY25 tax rate resulted from a renewed high-tech enterprise tax concession in China, confirmed in Dec'24, leading to the reversal of prior higher tax provisions under China's concessional tax framework.
- India's demand weakness is temporary, with management expecting a strong recovery in Beauty & Cosmetics sales, while Thailand's expansion will secure a larger share of the Southeast Asian market.
- Brazil's faster-than-expected capacity expansion reinforces its long-term growth potential, further strengthening EPL's position.
- Diversification into Beauty & Cosmetics, sustainability, and high-value markets is set to drive superior growth and margin expansion, with sustainable tubes now contributing 31% of total sales, up from 21% in FY24.
- EPL's NeoSeam technology and advanced printing capabilities continue to differentiate it in the Beauty & Cosmetics segment, supporting its long-term strategic roadmap despite near-term macroeconomic challenges.

#### Valuation and view


- EPL experienced strong growth in the Americas and Europe, driven by a favorable product mix, a trend we expect to sustain moving forward. Additionally, the recovery in AMESA and EAP markets will be supported by a scale-up in exports from India and further expansion into this region driven by the new facility in Thailand, respectively.
- We expect a CAGR of 9%/15%/27% in revenue/EBITDA/adjusted PAT over FY24-27. We value the stock at 18x FY27E EPS to arrive at our TP of INR300. Reiterate BUY.

**Exhibit 9: Revisions to our estimates** 

		Old			New		Change		
(INRm)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	42,793	46,921	51,081	41,896	45,944	50,026	-2%	-2%	-2%
EBITDA	8,602	10,023	11,074	8,256	9,771	10,789	-4%	-3%	-3%
Adj. PAT	3,472	4,684	5,525	3,377	4,485	5,301	-3%	-4%	-4%

Source: Company, MOFSL





Source: Company, MOFSL

MOTILAL OSWAL

# **Financials and valuations**

Consolidated - Income Statement									(INR m
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Total Income from Operations	27,069	27,614	30,916	34,328	36,941	39,161	41,896	45,944	50,026
Change (%)	11.7	2.0	12.0	11.0	7.6	6.0	7.0	9.7	8.9
Raw material cost	11,648	11,581	12,934	15,176	16,738	16,570	17,024	18,883	20,561
Employees Cost	5,006	5,311	6,064	6,500	6,895	7,725	8,383	8,959	9,605
Other Expenses	5,424	5,147	5,807	6,891	7,530	7,723	8,234	8,331	9,072
Total Expenditure	22,078	22,039	24,805	28,567	31,163	32,018	33,640	36,173	39,238
% of Sales	81.6	79.8	80.2	83.2	84.4	81.8	80.3	78.7	78.4
EBITDA	4,991	5,575	6,111	5,761	5,778	7,143	8,256	9,771	10,789
Margin (%)	18.4	20.2	19.8	16.8	15.6	18.2	19.7	21.3	21.6
Depreciation	1,861	2,298	2,346	2,514	2,805	3,328	3,471	3,837	4,054
EBIT	3,130	3,277	3,765	3,247	2,973	3,815	4,785	5,934	6,735
Int. and Finance Charges	613	556	429	403	674	1,156	1,125	494	256
Other Income	285	133	145	120	421	594	462	505	550
PBT bef. EO Exp.	2,802	2,854	3,481	2,964	2,720	3,253	4,122	5,945	7,030
EO Items	31	-94	-161	0	-11	-605	0	0	0
PBT after EO Exp.	2,833	2,760	3,320	2,964	2,709	2,648	4,122	5,945	7,030
Total Tax	932	638	868	675	373	582	777	1,496	1,769
Tax Rate (%)	32.9	23.1	26.1	22.8	13.8	22.0	18.8	25.2	25.2
Profit/loss from associates	53.2	-6.0	-9.0	-76	-29	35	-13	-14	-15
Minority Interest	29	43	52	69	40	-31	-45	-50	-55
Reported PAT	1,925	2,073	2,391	2,144	2,267	2,132	3,377	4,485	5,301
Adjusted PAT	1,895	2,167	2,552	2,144	2,278	2,586	3,377	4,485	5,301
Change (%)	7.3	14.4	17.8	-16.0	6.3	13.5	30.6	32.8	18.2
Margin (%)	7.0	7.8	8.3	6.2	6.2	6.6	8.1	9.8	10.6
Consolidated - Balance Sheet									(INRm)
	FV40	EV/20	EV/24	EV22	EV22	EV24	EVACE	EVACE	
Y/E March	<b>FY19</b> 631	FY20	<b>FY21</b> 631	<b>FY22</b> 632	<b>FY23</b> 636	<b>FY24</b> 637	<b>FY25E</b> 637	FY26E	FY27E
Equity Share Capital		631						637	637
Total Reserves Net Worth	13,249 <b>13,880</b>	14,695 <b>15,326</b>	16,350 <b>16,981</b>	17,613 <b>18,245</b>	19,256 <b>19,892</b>	20,278	22,063 <b>22,700</b>	24,955	28,663
	52	86	333	336	36	<b>20,915</b> -9	-9	<b>25,592</b> -9	<b>29,300</b> -9
Minority Interest Total Loans	6,313	6,432	5,536	6,572	7,686	8,040	6,040	3,840	1,840
Deferred Tax Liabilities	•	•		•	632	634	•		634
	510	475 <b>22,319</b>	543	619 <b>25,772</b>			634 <b>29,365</b>	634 <b>30,057</b>	31,765
Capital Employed Gross Block	<b>20,754</b> 20,495	22,434	<b>23,393</b> 25,500	27,236	<b>28,246</b> 32,147	<b>29,580</b> 37,803	39,673	41,973	44,273
Less: Accum. Deprn.	7,564	9,862	12,208	14,722	17,527	20,855	24,326	28,163	32,216
Net Fixed Assets	12,931	12,572	13,292	12,514	14,620	16,948	15,347	13,810	12,056
Goodwill on Consolidation	142	142					1,159		
	413	352	1,159 273	1,159	1,159	1,159 720	•	1,159	1,159
Capital WIP  Total Investments	168	160	149	1,466 <b>72</b>	1,780 <b>193</b>	720 <b>76</b>	1,150 <b>76</b>	1,150 <b>76</b>	1,150 <b>76</b>
Current Investments	0	0	0	0	150	0	0	0	
Curr. Assets, Loans&Adv.	11,547	14,833	15,241	17,715	18,552	19,184	20,573	<b>23,452</b>	2 <b>7,053</b>
	3,234			5,941	6,079				
Inventory Account Receivables	4,934	3,692 4,903	4,149 5,891	6,367	6,430	6,558 6,953	6,452 7,346	6,937	6,988
Cash and Bank Balance	1,344							8,056	8,772
Loans and Advances		3,715	2,414	1,927	2,444	2,073	2,924	4,236	6,695
Curr. Liability & Prov.	2,035	2,523 <b>5,740</b>	2,787 <b>6.721</b>	3,480 7.154	3,599	3,600	3,851	4,224	4,599
	<b>4,447</b>		6, <b>721</b>	<b>7,154</b>	<b>8,058</b>	<b>8,507</b>	<b>8,940</b>	<b>9,589</b>	<b>9,729</b>
Account Payables Other Current Liabilities	2,065	3,538	4,222	4,547	4,999	5,659	5,714	6,144	6,128
Other Current Liabilities	2,113	1,942	2,163	2,268	2,728	2,457	2,807	2,986	3,102
Provisions Not Current Assets	269 7 100	260	336	339	331	391	418	459	499
Net Current Assets	7,100	9,093	8,520	10,561	10,494	10,677	11,633	13,863	17,324
Misc Expenditure	0	0	0	0	0	0	0	0	0
Appl. of Funds	20,754	22,319	23,393	25,772	28,246	29,580	29,365	30,057	31,766

MOTILAL OSWAL

# **Financials and valuations**

Ratios						_			
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	5.9	6.8	8.0	6.7	7.2	8.1	10.6	14.1	16.6
Cash EPS	11.8	14.0	15.4	14.6	16.0	18.6	21.5	26.1	29.4
BV/Share	43.6	48.1	53.3	57.3	62.5	65.7	71.3	80.4	92.0
DPS	1.2	3.3	4.1	4.2	4.3	4.3	5.0	5.0	5.0
Payout (%)	23.6	57.1	54.6	62.4	60.4	64.2	47.2	35.5	30.0
Valuation (x)									
P/E	41.9	36.7	31.1	37.1	34.9	30.7	23.5	17.7	15.0
Cash P/E	21.2	17.8	16.2	17.1	15.6	13.4	11.6	9.6	8.5
P/BV	5.7	5.2	4.7	4.4	4.0	3.8	3.5	3.1	2.7
EV/Sales	3.1	3.0	2.7	2.5	2.3	2.2	2.0	1.7	1.5
EV/EBITDA	16.9	14.8	13.6	14.7	14.6	12.0	10.0	8.1	6.9
Dividend Yield (%)	0.5	1.3	1.6	1.7	1.7	1.7	2.0	2.0	2.0
FCF per share	1.8	8.9	5.7	1.4	6.7	4.0	15.9	15.8	17.9
Return Ratios (%)									
RoE	14.4	14.8	15.8	12.2	11.9	12.7	15.5	18.6	19.3
RoCE	11.5	12.5	13.0	11.0	11.2	12.2	14.8	16.6	18.0
RoIC	11.4	13.6	14.4	11.7	11.1	11.8	15.0	17.8	20.8
Working Capital Ratios									
Fixed Asset Turnover (x)	1.3	1.2	1.2	1.3	1.1	1.0	1.1	1.1	1.1
Asset Turnover (x)	1.3	1.2	1.3	1.3	1.3	1.3	1.4	1.5	1.6
Inventory (Days)	44	49	49	63	60	61	56	55	51
Debtor (Days)	67	65	70	68	64	65	64	64	64
Creditor (Days)	28	47	50	48	49	53	50	49	45
Leverage Ratio (x)									
Current Ratio	2.6	2.6	2.3	2.5	2.3	2.3	2.3	2.4	2.8
Interest Cover Ratio	5.1	5.9	8.8	8.1	4.4	3.3	4.3	12.0	26.4
Net Debt/Equity	0.4	0.2	0.2	0.3	0.3	0.3	0.1	0.0	-0.2
,									
Consolidated - Cash Flow Statement									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	2,886	2,854	3,311	2,888	2,680	3,253	4,122	5,945	7,030
Depreciation	1,861	2,298	2,346	2,514	2,805	3,328	3,471	3,837	4,054
Interest & Finance Charges	380	423	381	355	674	562	663	-11	-295
Direct Taxes Paid	-901	-638	-866	-776	-449	-582	-777	-1,496	-1,769
(Inc)/Dec in WC	-404	-127	-380	-2,217	136	-126	-106	-918	-1,002
CF from Operations	3,821	4,811	4.792	2,764	5.846	6,435	7.374	7,357	8,017
Others	-257	-100	432	353	172	-570	-13	-14	-15
CF from Operating incl EO	3,564	4,711	5,224	3,117	6,018	5,865	7,361	7,343	8,003
(Inc)/Dec in FA	-3,003	-1,878	-3,396	-2,668	-3,871	-4,596	-2,300	-2,300	-2,300
Free Cash Flow	561	2,833	1,828	449	2,147	1,269	5,061	5,043	5,703
(Pur)/Sale of Investments	2	8	5	443	-147	117	0	0	0
Others	1,122	680	586	22	126	1,036	462	505	550
CF from Investments	-1,879	- <b>1,190</b>	- <b>2,805</b>	-2,642	-3,892	-3,443	-1,838	- <b>1,795</b>	- <b>1,750</b>
Issue of Shares	53	0	- <b>2,803</b>	50	- <b>3,892</b>	-5,445	0	0	0
Inc/(Dec) in Debt	-1,028	119	-1,219	1,031	1,386	354	-2,000	-2,200	-2,000
Interest Paid	-485	-556						-494	
Dividend Paid	-485 -478	-1,184	-321	-278 -1 380	-575 -1,362	-1,156 -1,370	-1,125 -1 503		-256 -1 503
			-1,341	-1,380		-1,370	-1,593	-1,593	-1,593
Others CE from Ein Activity	-138	469	-317	-377	-832	-633	45	50	55
CF from Fin. Activity	-2,076	-1,152	-3,191	-954	-1,383	-2,804	-4,672	-4,237	-3,793
Inc/Dec of Cash	- <b>391</b>	2,369	- <b>772</b>	-4 <b>79</b>	<b>743</b>	-382	8 <b>50</b>	1,312	2,459
Opening Balance	1,735	1,344	3,116	2,414	1,927	2,444	2,073	2,924	4,236
Closing Balance	1,344	3,707	2,414	1,927	2,444	2,073	2,924	4,236	6,695

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating				
Investment Rating	Expected return (over 12-month)			
BUY	>=15%			
SELL	< - 10%			
NEUTRAL	< - 10 % to 15%			
UNDER REVIEW	Rating may undergo a change			
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation			

In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited \_ MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dormant/com/Dorma MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at

https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.co have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered (qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MCCMSPL. In respect of any matter arising from or in connection with the research you could contact the following representatives of MCCMSPL. In case of grievances for any of the services rendered by MCCMSPL.

write to grievances@motilaloswal.com

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No. Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
  - MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months. MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

  MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies)
- 8. in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

11 February 2025 9

- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

Grievance Redressal Cell-

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Choranoo Nodrooda Goll.							
Contact Person	Contact No.	Email ID					
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com					
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com					
Mr. Ajay Menon	022 40548083	am@motilaloswal.com					

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

11 February 2025